CEVIPABULIN FUMARATE (C15-1722-084)

Catalog No.: C15-1722-084
Mfr. No.: SML2671-5MG
Mfr. Name: Sigma-Aldrich
Qty/UOM: 5
UOM: MG

Price: $237.03

List Price: $263.36

Biochem/physiol Actions Cevipabulin (TTI-237) is a potent microtubule-stabilizing agent that binds to tubulin vinblastine binding site, a typical site of binding for microtubule-destabilizing agents. It is likely that cevipabulin, similarly to

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Adding to cart… The item has been added

Description
Specifications

Biochem/physiol Actions

Cevipabulin (TTI-237) is a potent microtubule-stabilizing agent that binds to tubulin vinblastine binding site, a typical site of binding for microtubule-destabilizing agents. It is likely that cevipabulin, similarly to other triazolopyrimidines, promotes longitudinal tubulin contacts in microtubules, which promotes stabilization of micro-tubule. Cevipabulin exhibits potent cytotoxic activity in cancer cell lines including cell line expressing a high level of P-glycoprotein. It is active in vivo in several mouse xenograft models of human cancer.

UPC:: 12352200
Condition:: New
Availability:: 3-5 Days
Weight:: 1.00 Ounces
HazmatClass:: No
MPN:: SML2671-5MG
CAS:: 849550-67-0

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."